The European Hematology Association (EHA) is a non-profit membership organization headquartered in The Hague, Netherlands.
It promotes excellence in hematology through education, research, advocacy, and professional development across Europe and beyond.
EHA connects hematology professionals, supports competency-based training, and organizes the annual EHA Congress to share scientific advancements and improve patient outcomes.
Also known as European Hematology Association (EHA).
None yet. When a new project in the record names EHA as owner, partner or investor, it shows here.
sBLA accepted for subcutaneous bispecific + ADC combo in relapsed/refractory large B‑cell lymphoma; FDA decision expected Feb 9, 2027.
Phase 3 BRUIN CLL-322 found adding pirtobrutinib to a two‑year venetoclax+rituximab regimen reduced progression or death by 45% versus venetoclax+rituximab alone.
Phase 1 data show 70% SVR35 and TSS50 rates, VAF reductions in 21/23 patients, no dose‑limiting toxicities; expansion and further indications planned.
Post‑hoc subgroup analysis of the Phase 3 EPCORE FL‑1 shows epcoritamab+rituximab+lenalidomide delivers consistent PFS, ORR and CRR gains with a manageable safety profile across risk and fitness subgroups.
